Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China

被引：0
|
作者：
Lifeng Mu
Benhong Zhou
机构：
[1] Renmin Hospital of Wuhan University,Department of Pharmacy
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Alectinib; China; Cost-effectiveness; Non-small-cell lung cancer; Oncology; Survival extrapolation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：968 / 970
页数：2
相关论文
共 50 条
  • [31] ALECTINIB FOR THE TREATMENT OF ALK-POSITIVE STAGE IV NON-SMALL CELL LUNG CANCER
    Wong, K. M.
    Noonan, S.
    O'Bryant, C.
    Jimeno, A.
    DRUGS OF TODAY, 2015, 51 (03) : 161 - 170
  • [32] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [33] Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer
    Rusthoven, Chad G.
    Doebele, Robert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2814 - +
  • [34] Primary resistance to ALK inhibitor in ALK-positive non-small-cell lung cancer.
    Kang, Jin
    Chen, Huajun
    Zhou, Qing
    Tu, Hai-Yan
    Zhang, Xu-Chao
    Jian, Su
    Wang, Zhen
    Wang, Bin-Chao
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
  • [36] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
    Yang, X.
    Dong, X.
    Liu, Y.
    Jin, B.
    Wang, J.
    Wang, Y.
    Zhang, Y.
    Zhuo, M.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S663 - S663
  • [37] Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory
    Li, Yimeng
    Hao, Zhanpeng
    Ma, Yuyan
    Setiwalidi, Kaidiriye
    Zhang, Yingming
    Zhao, Yujia
    Fu, Xiao
    Liang, Xuan
    Ruan, Zhiping
    Tian, Tao
    Yao, Yu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) : 152 - 162
  • [38] The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective
    Cranmer, Holly
    Kearns, Isabella
    Young, Melanie
    Humphries, Michael J.
    Trueman, David
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 970 - 979
  • [39] Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study
    Yin, Qiang
    Li, Peng
    Wang, Peng
    Zhang, Zhen
    Liu, Qun
    Sun, Zengfeng
    Li, Wenliang
    Ma, Li
    Wang, Xiaoguang
    ONCOTARGETS AND THERAPY, 2021, 14 : 5533 - 5542
  • [40] Cost-effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China
    Zhang, Xudong
    Fang, Pingping
    Su, Guangquan
    Gui, Shuangying
    Shen, Aizong
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (12) : 871 - 878
12345